INS and type 1 diabetes mellitus: While the majority of the studies included in the above-mentioned meta-analysis were of short duration, a 1-year intervention-based placebo-controlled trial of 100 individuals with poorly controlled T1D (HbA1c ≥ 8.5%) revealed no benefits on glucose control, but similar advantages in terms of reducing body weight and the total daily insulin dose.